

1 **Full title: HIV-1 RNA in Large and Small Plasmatic Extracellular**
2 **Vesicles: a Novel Parameter for Monitoring Immune Activation**
3 **and Virological Failure**

4 **Authors: Julien Boucher¹, Wilfried Wenceslas Bazié^{1, 2}, Benjamin Goyer¹, Michel**
5 **Alary^{3,4,5} and Caroline Gilbert^{1, 6*}**

6 ¹ Axe de Recherche Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de
7 Québec-Université Laval, Québec, QC, Canada

8 ² Programme de Recherche sur les Maladies Infectieuses, Centre Muraz, Institut National de
9 Santé Publique, Bobo-Dioulasso, Burkina Faso

10 ³ Axe de Recherche Santé des Populations et Pratiques Optimales en Santé, Centre de
11 Recherche du CHU de Québec-Université Laval, Québec, QC G1S 4L8, Canada;

12 ⁴ Département de Médecine Sociale et Préventive, Faculté de Médecine, Université Laval,
13 Québec, QC G1V 0A6, Canada

14 ⁵ Institut National de Santé Publique du Québec, Québec, QC G1V 5B3, Canada

15 ⁶ Département de Microbiologie-Infectiologie et d'Immunologie, Faculté de Médecine,
16 Université Laval, Québec, Canada

17 ***Correspondence:**

18 Caroline Gilbert (C.G.)

19 caroline.gilbert@crchudequebec.ulaval.ca (C.G.); Ph: +1-418-525-4444 ext. 46107; Fax: +1-

20 418-654-2765

21 **Abstract**

22 **Background:** Antiretroviral therapy (ART) suppresses viral replication in most people living
23 with HIV-1 (PLWH). However, PLWH remain at risk of viral rebound. HIV-1 infection
24 modifies the content of extracellular vesicles (EVs). The changes in microRNA content in EVs
25 are biomarkers of immune activation and viral replication in PLWH. Moreover, viral molecules
26 are enclosed in EVs produced from infected cells. Our objective was to assess the value of EV-
27 associated HIV-1 RNA as a biomarker of immune activation and viral replication in PLWH.

28 **Methods:** Plasma samples were obtained from a cohort of 53 PLWH with a detectable viremia.
29 Large and small EVs were respectively purified by plasma centrifugation at 17,000 x g and by
30 precipitation with ExoQuick™. HIV-1 RNA and microRNAs were quantified in the EV
31 subtypes by RT-qPCR.

32 **Findings:** HIV-1 RNA content was higher in large EVs of ART-naïve PLWH. Small EVs HIV-
33 1 RNA was equivalent in ART-naïve and ART-treated PLWH and positively correlated with
34 CD4/CD8 T cell ratio. In ART-naïve PLWH, HIV-1 RNA content of large EVs correlated with
35 small EV-associated miR-29a, miR-146a and miR-155, biomarkers of viral replication and
36 immune activation. A receiver operating characteristics analysis showed that HIV-1 RNA in
37 large EVs discriminated PLWH with a high CD8 T cell count.

38 **Interpretation:** HIV-1 RNA in large EVs was associated with viral replication and immune
39 activation biomarkers. Inversely, HIV-1 RNA in small EVs was related to immune
40 restoration. Overall, these results suggest that HIV-1 RNA quantification in purified EVs could
41 be a useful parameter to monitor HIV-1 infection.

42 **Funding:** Canadian Institutes of Health Research (CIHR) grants MOP-391232; MOP-188726;
43 MOP-267056 (HIV/AIDS initiative)

44 **Keywords (3-5):** extracellular vesicles subtypes, HIV-1 RNA, immune activation, virological
45 failure

46

47 **Research in context**

48 **Evidence before this study**

49 Antiretroviral therapy (ART) suppress viral replication to make HIV-1 infection manageable,
50 but fails to clear the virus from people living with HIV-1 (PLWH). Hence, the infection
51 becomes a chronic condition characterized by a dysfunction of the immune system caused by
52 repeated activation and a persistent risk of a resurgence of viral replication (viral rebound). New
53 biomarkers are required to improve the care of PLWH by identifying the individuals with a
54 greater immune dysfunction and/or a higher risk of viral rebound. HIV-1 infection modifies the
55 abundance, size and content of plasmatic extracellular vesicles (EVs). Specific host microRNAs
56 enrichment in EVs correlates with immune activation and viral rebound. In addition, viral
57 proteins and genomic material are found within EVs. Various EV subtypes are released by
58 infected cells, all using different biogenesis machinery. The distribution of HIV-1 RNA in EV
59 subtypes has never been assessed and this novel parameter could provide information on the
60 infection progression.

61 **Added value of this study**

62 This study provides the first quantification of HIV-1 RNA in two EV subtypes, large and small,
63 from the plasma of PLWH. Large EVs HIV-1 RNA was lower in ART-treated PLWH and
64 decreased with the duration of treatment. HIV-1 RNA associated to large EVs was a better
65 predictor of immune activation than the standard plasma viral load. Inversely, the HIV-1 RNA
66 concentration in small EVs was unaffected by ART and linked to better immune functions.
67 Overall, the results presented in this study suggest that HIV-1 RNA in large EVs originates
68 from ongoing viral replication, while HIV-1 in small EVs is the produce of proviral
69 transcription.

70 **Implications of all the evidence**

71 The standard procedure for the clinical care of PLWH is to quantify HIV-1 RNA in the whole
72 plasma, disregarding the context of its production. We show that the differential distribution of
73 HIV-1 RNA in large and small EVs seems to be an indicator of disease progression. The
74 purification of plasmatic EVs is considered as a non-invasive liquid biopsy to assess the
75 progression of diseases. PLWH could benefit from the analysis of their plasmatic EVs to
76 monitor the infection with an improved precision.

77 **1. Introduction**

78 Forty years have passed since the outbreak of the HIV-1 pandemic (1). The greatest progress
79 in fighting HIV-1 infection was the discovery of molecules that inhibit HIV-1 replication (2).
80 This led to the implementation of antiretroviral therapy (ART), which remains to this day the
81 only way to manage HIV-1 infection (3). ART blocks HIV-1 replication in people living with
82 HIV-1 (PLWH), but viral reservoirs persist. Consequently, ART must be taken daily by PLWH
83 to avoid viral rebound and plasmatic viral load has to be measured every six months to ensure
84 viremic control (4).

85
86 Virological failure is either caused by treatment resistance or loss of treatment adherence (5).
87 Due to virological failure, CD4 T lymphocyte count plummets and the treatments must be
88 optimized (6). Some PLWH have a detectable low-level viremia defined as non-suppressible
89 viremia (NSV) (7, 8). Despite many years of ART, NSV occurs without the apparition of
90 treatment resistance, and cannot be suppressed by treatment intensification (9). NSV originates
91 from defective or replication-competent provirus transcriptional activity of infected T cell
92 clones rather than new infection events (7). PLWH with NSV have an immune activation level
93 similar to ART-suppressed PLWH (10). To summarize, a positive viral load assay could
94 indicate an ongoing virus replication that requires immediate treatment optimization, or viral
95 expression from latently infected cells for which treatment optimization is unnecessary (8).
96 Thus, there is a need to understand better the mechanisms and the context behind detectable
97 viremia in PLWH to facilitate their clinical care (8).

98
99 In recent years, the roles of extracellular vesicles (EVs) as biomarkers and a non-invasive tool
100 to monitor the HIV-1 disease progression have emerged (11-13). EVs are nanoparticles
101 enclosed by a bilayered lipid membrane (14). They are separated into two major subclasses

102 depending on their origin. The first class, microvesicles, is named large EVs in this article.
103 Large EVs are the product of the membrane budding (15). The second class is exosomes, called
104 small EVs in this paper. Small EVs originate from the inward budding of endosomes and are
105 released in the extracellular environment when endosomes merge with the plasma membrane
106 (16). The endosomal sorting complex required for transport (ESCRT) machinery is the major
107 pathway of small EVs biogenesis (16). Cargo selection in EVs subtypes is simultaneously a
108 passive and active process. It is passive because cytoplasm and membrane content can be
109 randomly selected in EVs. As a result, component concentration in EVs changes according to
110 cellular expression. The EV biogenesis machinery drives the active cargo selection process.
111 Consequently, active cargo selection varies between EV subtypes and can increase cargo
112 concentration independently of cellular expression changes (17).

113
114 HIV-1 infection modifies the host microRNA content of EVs (18). Enrichment of miR-29a,
115 miR-146a and miR-155 in small EVs of PLWH under ART was a predictor of detectable
116 viremia (12). MiR-155 in large EVs of PLWH under ART was a predictor of immune activation
117 (19). MiR-155-enriched EVs enhanced HIV-1 infection and promoted inflammation in
118 recipient cells (18). Due to the similarities between EVs and HIV-1 biogenesis, infected cells
119 release EVs harbouring viral RNA and proteins (20, 21). The unspliced genomic RNA of HIV-
120 1 and the transactivation response element (TAR) RNA sequence were measured in the EVs
121 released by infected cells (20-22). Inhibition of the ESCRT pathway lowers HIV-1 RNA
122 concentration in EVs, showing its role in viral RNA sorting to EVs (22). Moreover, HIV-1
123 RNA in EVs persists despite ART, even when the plasma viral load is undetectable (23).

124
125 Since EV subtypes have different biogenesis pathways and we have shown differential
126 biomarker roles for large and small plasmatic microRNA in EVs, we hypothesized that ART

127 influences the viral RNA distribution in both EVs subtypes of PLWH. This new measurement
128 could be a future biomarker for HIV infection management. The present study showed that
129 large EVs were more abundant and contained more HIV-1 RNA in ART-naive PLWH and
130 HIV-1 RNA in small EVs was unaffected by ART but correlated with the CD4/CD8 ratio.

131 **2. Methods**

132 **2.1 Study participants**

133 The cohort of PLWH present in this study ($n = 53$) was selected from a larger cohort of PLWH
134 recruited in Bobo-Dioulasso and Ouagadougou (Burkina Faso) (12, 19, 24). These participants
135 were selected because they had a detectable plasma viral load at their recruitment. All
136 participants were anonymous volunteers and provided written informed consent.

137

138 **2.2 Plasma EVs purification**

139 Plasma EVs purification was performed according to a well-established procedure (11, 24, 25).
140 Platelet-free plasma (250 μ L) was thawed at room temperature and treated with proteinase K
141 (1.25 mg/mL) for 10 minutes at 37 °C to eliminate protein aggregates and extravesicular RNA.
142 Then, the plasma was centrifuged at 3,000 $\times g$ for 15 minutes to discard apoptotic vesicles, and
143 at 17,000 $\times g$ for 30 minutes to pellet large EVs. The remaining supernatant was mixed with 63
144 μ L ExoQuick™ (System Biosciences) reagent and incubated at 4 °C overnight. A centrifugation
145 at 1,500 $\times g$ for 30 minutes precipitated small EVs. EV pellets were washed with 0.22 μ m
146 filtered PBS and resuspended in 250 μ L of 0.22 μ m filtered PBS.

147

148 **2.3 Hydrodynamic size measurement**

149 Quality, homogeneity and size of EV samples were analyzed by dynamic light scattering (DLS)
150 with a Zetasizer Nano ZS (Malvern Instruments). Hydrodynamic diameter measurements were
151 done in duplicate at room temperature.

152

153 **2.4 EV quantification by flow cytometry**

154 Absolute EVs quantification by flow cytometry was performed as previously described (12).
155 EVs were stained with lipophilic carbocyanine DiD dye and CellTrace™ CFSE (ThermoFisher
156 Scientific), at a final concentration of 5 µM. DiD+ and CFSE+ events were considered EVs.
157 EV concentration in our samples was determined with 15 µm silica beads (Polybead®
158 Microspheres, Polysciences). The acquisition was performed on a modified BDFACS canto II
159 with a photomultiplier on the forward scatter (FSC) channel to improve nanoparticle
160 detection.

161

162 **2.5 RNA extraction**

163 RNA was extracted from 50 µL of purified EVs (diluted in three volumes of Trizol® LS
164 (ThermoFisher Scientific) using the phenol/chloroform method and resuspended in 15 µL of
165 Tris/EDTA buffer (18, 26). RNA concentration was measured using a BioDrop™
166 spectrophotometer (Montreal Biotech Inc.).

167

168 **2.6 HIV-1 RNA quantification**

169 RT-PCR was performed on 5 µL of RNA with the Superscript IV reverse transcriptase kit
170 (ThermoFisher Scientific) according to the manufacturer instructions with a final concentration
171 of 10nM of primer set on a GeneAmp® PCR System 9700 (Applied Biosystems) (27). The
172 primers were obtained from Integrated DNA Technologies: forward: 5'-
173 GCCTCAATAAAGCTTGCCTTGA-3'; reverse: 5'- GGCGCCACTGCTAGAGATTTT -3' to
174 target the 3' LTR region of the HIV-1 genome (NCBI accession number: K03455.1). CDNA
175 was pre-amplified as described before (28). QPCR reactions were performed with the
176 QuantiTech SyBr Green kit (Qiagen) according to the manufacturer's instructions on a CFX384
177 Touch Real-Time PCR Detection System (Bio-Rad) (28).

178

179 **2.7 MiRNA quantification by RT-qPCR**

180 Reverse transcription was achieved using the miScript RT kit (Qiagen) in a GeneAmp® PCR
181 System 9700 (Applied Biosystems) (18). Quantitative PCR was conducted in 96-well plates
182 (Multiplate™, BioRad©) with miScript SyBr® Green from Qiagen© using a CFX Connect™
183 Real-time system (Bio-Rad©). The primers for miR-29a (Cat: MS00003262), miR-146a (Cat:
184 MS00006566) and miR155 (Cat: MS00031489) were purchased from Qiagen©.

185

186 **2.8 Statistical analysis**

187 Normal and lognormal distribution tests were carried out for all data sets. Data sets with a
188 lognormal distribution were transformed to obtain a normal distribution for statistical analysis.
189 Statistical analyses were carried out using GraphPad Prism software version 10.2.2 with p-
190 values below 0.05 considered statistically significant.

191

192 3. Results

193 3.1 HIV-1 RNA and microRNA distribution in large and small plasmatic EVs 194 of PLWH


195 The distribution of viral RNA between large and small EVs and the impact of ART treatment
196 were analyzed in a cohort of 53 PLWH with detectable viral load. Clinical characteristics
197 presented in Table 1 show that 14 were ART-naive and 39 were ART-treated. The median age
198 of ART-naive and ART-treated participants was 37 (interquartile range (IQR) 28-43) and 32
199 (27-43), respectively ($p = 0.4165$). ART-naive participants were living with HIV-1 for a median
200 duration of 5 months (IQR 1-51) and ART-treated for 26 (IQR 10-43) ($p = 0.2497$). Treated
201 participants were receiving ART for 24 months (IQR 7-66). The median CD4 T cell count, CD8
202 T cell count, and CD4/CD8 ratio were respectively 607 (IQR 264-762), 837 (IQR 515-1043)
203 and 0.7 (IQR 0.4-1.2) for ART-naive participants and 332 (IQR 182-469), 667 (IQR 522-926)
204 and 0.5 (IQR 0.2-0.7) for ART-treated participants. The plasma viral load median was higher
205 for the ART-Naive at 18,622 copies/mL (IQR 4,472-55,063) than for the ART-treated
206 participants at 9,373 (300-52,038).

207 **Table 1. Characteristics of the study participants.**
208

	ART-Naive (n = 14)	ART (n = 39)	<i>p</i> -value
Men, n (%)	5 (35.7)	19 (48.7)	
Women, n (%)	9 (64.3)	20 (51.3)	
Age (years); median (IQR)	37 (28-43)	32 (27-43)	0.4165
HIV duration (months); median (IQR)	5 (1-51)	26 (10-43)	0.2497
CD4 T cells/ μ L; median (IQR)	607 (264-762)	332 (182-469)	0.0467
CD8 T cells/ μ L; median (IQR)	837 (515-1043)	667 (522-926)	0.6006
CD4/CD8 ratio; median (IQR)	0.7 (0.4-1.2)	0.5 (0.2-0.7)	0.0403
ART duration (month); median (IQR)	NA	24 (7-66)	
Plasma viral load (copies/mL); median (IQR)	18,622 (4,472-55,063)	9,373 (300-52,038)	0.6159

ART: antiretroviral therapy; IQR: Interquartile range; NA: not applicable

209 Large and small EVs were purified from the plasma of PLWH with a detectable viral load as
 210 previously described (11, 12). As expected, large EVs from ART-naive PLWH (324 ± 31 nm)
 211 and ART-treated (364 ± 24 nm) had a bigger hydrodynamic diameter than the small EVs of
 212 ART-naive PLWH (86 ± 8.9 nm) and ART-treated (87 ± 4.8 nm) (Figure 1A). Absolute
 213 quantification by flow cytometry revealed that ART-naive PLWH large EVs were more
 214 concentrated ($1.52 \times 10^7 \pm 1.80 \times 10^6$ EVs/mL) than ART-treated PLWH ($8.46 \times 10^6 \pm 1.15 \times$
 215 10^6 EVs/mL) (Figure 1B). In addition, ART did not affect the count of small EVs since ART-
 216 naive PLWH small EVs were at a concentration of $1.76 \times 10^7 \pm 3.51 \times 10^6$ EVs/mL and ART-
 217 treated PLWH small EVs concentration was $1.35 \times 10^7 \pm 2.67 \times 10^6$ EVs/mL (Figure 1B).



218
 219
 220
 221
 222
 223

Figure 1. Viral RNA distribution in plasmatic EV subtypes from PLWH.


EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at $17,000 \times g$ to pellet large EVs, followed by ExoQuick precipitation to obtain small EVs. **A**. EV hydrodynamic size measurement by dynamic light scattering. **B**. Large and small EVs absolute concentration was determined by flow cytometry. **C**. Comparison of large and small EV-associated HIV-1 in ART-naive and ART-treated PLWH. **D**. The number of copies of HIV-

224 1 RNA per mL of sample was divided by the number of EVs per mL of sample to estimate the number of HIV-1
225 copies per EV. Statistical analysis was carried out by one-way ANOVA (* $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$).
226 ART: antiretroviral therapy; EV: extracellular vesicles; PLWH: people living with HIV-1.
227

228 Then, HIV-1 RNA was quantified by RT-qPCR in both types of EVs. HIV-1 RNA
229 concentration was higher in large EVs ($1.48 \times 10^5 \pm 4.02 \times 10^4$ copies/mL) and small EVs (1.07
230 $\times 10^5 \pm 2.09 \times 10^4$ copies/mL) than in the plasma ($5.57 \times 10^4 \pm 1.61 \times 10^4$ copies/mL) (Figure
231 S1). The difference between ART-treated ($2.72 \times 10^5 \pm 1.24 \times 10^4$ copies/mL) and ART-naive
232 PLWH ($1.03 \times 10^5 \pm 3.05 \times 10^4$ copies/mL) was most notable in large EVs (Figure 1C). HIV-1
233 RNA concentration in small EVs was similar in ART-naive ($1.41 \times 10^5 \pm 6.02 \times 10^4$ copies/mL)
234 and ART-treated PLWH ($9.49 \times 10^4 \pm 1.87 \times 10^4$ copies/mL) (Figure 1C). With absolute EV
235 concentrations, HIV-1 RNA copies per EV was calculated. In terms of HIV RNA per EV,
236 differences between ART-naive (large: 0.021 ± 0.007 copies/mL; small: 0.014 ± 0.007
237 copies/mL) and ART-naive PLWH (large: 0.017 ± 0.005 copies/mL; small: 0.011 ± 0.003
238 copies/mL) were minimal (Figure 1D). Thus, the higher HIV-1 RNA content in large EVs of
239 ART-naive PLWH was likely the result of increased production of large EVs containing HIV-
240 1 RNA rather than the enrichment of HIV-1 RNA in large EVs. The results showed that ART
241 decreased HIV RNA concentration in large EVs.
242

243 We previously showed a link between viral rebound and immune activation in PLWH and miR-
244 29a, miR-146a and miR-155 content in plasmatic EVs (12, 19). Quantification of three
245 microRNAs in large and small EVs by RT-qPCR showed that miR-155 was predominant in
246 large EVs of ART-naive PLWH (Figure S2A-B), while miR-146 and miR-29a were
247 significantly enriched in small EVs (Figure S2C-F). A correlation analysis showed that large
248 EVs and small EVs HIV-1 RNA in ART-naive PLWH correlated with miR-29a, miR-146 and
249 to a lesser extent with miR-155 concentration in small EVs (Figure 2A and C). These results
250 strengthened the viral rebound biomarker potential of miRNAs in small EVs. Conversely, in

251 ART-treated PLWH, no correlation was found between large or small EVs HIV-1 RNA and
 252 small EVs miRNA content (Figure 2B and D). In addition, no correlation was found between
 253 large or small EVs HIV-1 RNA and large EVs miRNA content (Figure S3).



254
 255 **Figure 2. Separated correlation analysis between EV-associated viral load and miRNAs in ART-receiving**
 256 **and ART-naive PLWH.**


257 EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at 17,000 x g to pellet large
 258 EVs, followed by ExoQuick precipitation to obtain small EVs. Viral load and miRNAs content in EVs were
 259 quantified by RT-qPCR in large and small EVs. **A.** Correlation analysis between HIV-1 RNA concentration in
 260 large EVs and miRNAs concentration in small EVs of ART-naive PLWH. **B.** Correlation analysis between HIV-
 261 1 RNA concentration in large EVs and miRNAs concentration in small EVs of PLWH under ART. **C.** Correlation
 262 analysis between HIV-1 RNA concentration and miRNAs concentration in small EVs of ART-naive PLWH. **D.**
 263 Correlation analysis between HIV-1 RNA concentration and miRNAs concentration in small EVs of PLWH under
 264 ART. ART: antiretroviral therapy; EV: extracellular vesicles; PLWH: people living with HIV-1.

265

266


267 3.2 HIV-1 RNA in plasmatic EV subtypes of PLWH is associated with 268 biomarkers of HIV-1 pathogenesis

269 Correlation analysis between large and small EVs HIV-1 RNA content and clinical parameters
270 was performed to determine if HIV-1 RNA quantification in EVs is a better predictor of disease
271 progression than the conventional plasma measurement. HIV-1 RNA measurement in the
272 plasma correlated with the large EVs HIV-1 RNA measurement (Figure 3A). In ART-treated
273 PLWH, large EVs HIV-1 RNA diminished with time under ART (Figure 3B). Conversely, in
274 small EVs, HIV-1 RNA concentration was unaffected by ART (Figures 1C and 3B) There was
275 a positive association between HIV-1 RNA in small EVs and the CD4/CD8 ratio (Figure 3C).



276
277 **Figure 3. Correlation analysis between EV-associated HIV-1 RNA and biomarkers of infection progression.**
278 EVs were purified from platelet-free and proteinase K-treated plasma by centrifugation at $17,000 \times g$ to pellet large
279 EVs, followed by ExoQuick precipitation to obtain small EVs. HIV-1 RNA was quantified by RT-qPCR in large
280 and small EVs. **A.** Correlation analysis between the plasma viral load and the purified EV-associated viral load.
281 **B.** Correlation analysis between the time receiving ART and plasma and EVs HIV-1 RNA. **C.** Correlation between
282 the CD4/CD8 ratio and plasma and EVs viral load. ART: antiretroviral therapy; EV: extracellular vesicles.
283

284 Next, we evaluated the potential of EV-associated HIV-1 RNA as a parameter to discriminate
285 PLWH with immune activation and dysfunction. Among the 53 participants, those with a CD8
286 T cell count above 500 cells/ μ L were designated with immune activation ($n = 41$). The
287 remaining participants with a CD8 T cell count below 500 cells/ μ L were in the control group
288 ($n = 12$). A receiver operating characteristics (ROC) curve analysis was performed to determine
289 which HIV-1 RNA concentration in the plasma, large EVs or small EVs discriminates PLWH
290 with immune activation. HIV-1 RNA in the plasma (AUC = 0.50; 95% CI = 0.29-0.71; $p =$
291 0.9661) (Figure 4A) and the small EVs (AUC = 0.62; 95% CI = 0.43-0.80; $p = 0.2257$) (Figure
292 4C) could not distinguish PLWH with immune activation. HIV-1 RNA concentration in large
293 EVs had the best diagnosis performance (AUC = 0.66; 95% CI = 0.50-0.83; $p = 0.0852$) (Figure
294 4B). PLWH with a CD4 count below 500 cells/ μ L ($n = 38$) or a CD4/CD8 ratio below 1 ($n =$
295 45) was designated with immune impairment. The participants with a CD4 T cell count above
296 500 cells/ μ L ($n = 15$) or a CD4/CD8 ratio above 1 ($n = 8$) were the controls. HIV-1 RNA in the
297 plasma discriminated PLWH with immune impairment (Figure S4A and D), while HIV-1 RNA
298 in large (Figure S4B-E) and small EVs (Figure S4C-F) did not. Overall, HIV-1 RNA in the
299 plasma discriminated PLWH with low CD4 T cell count and CD4/CD8 ratio, while HIV-1 RNA
300 in large EVs best discriminated PLWH with high CD8 T cell count.



301
302 **Figure 4. Diagnosis performance of immune activation by HIV-1 RNA concentrations in the plasma and**
303 **EVs subtypes.**

304 HIV-1 RNA concentrations in the plasma and EV subtypes were used for ROC analysis to discriminate participants
305 with immune activation. The participants with a CD8 T cell count below 500/ μ L were the controls. A CD8 T cell
306 count above 500/ μ L defined immune activation. **A.** ROC curve of HIV-1 RNA concentration in the plasma. **B.**
307 ROC curve of HIV-1 RNA concentration in large EVs. **C.** ROC curve of HIV-1 RNA concentration in small EVs.
308 ROC: Receiver Operating Characteristics

309

310 **4. Discussion**

311 Decades of suppressive ART fails to clear viral reservoirs. Hence, PLWH are permanently at
312 risk of viral rebound (4). When viremia is detected in PLWH, ART regimen modification or
313 intensification is not always necessary and characterization of the virus in the plasma of PLWH
314 could assist in HIV-1 infection management (8). This study aimed to quantify HIV-1 RNA in
315 both types of plasmatic EVs of PLWH towards a more personalized HIV-1 infection
316 management. We found that the value of small and large EV-associated HIV-1 RNA are
317 biomarkers of disease progression and viral replication.

318

319 We previously reported an increase in total EVs concentration in ART-naive PLWH (13). Here,
320 only the large EVs concentration was higher in ART-naive PLWH than PLWH under ART.
321 Our results suggest that large EVs probably caused the increase in total EV concentration
322 observed by Hubert et al. (13). The large EVs HIV-1 RNA level was higher in ART-naive
323 PLWH than in treated PLWH. In PLWH under ART, HIV-1 RNA in large EVs was negatively
324 correlated with time under ART. Interestingly, HIV-1 RNA concentration in small EVs was
325 unaffected by ART. The persistence of HIV-1 RNA in small EVs despite ART is reminiscent
326 of NSV, which is unaffected by ART (9). NSV has been more associated with men (29). Our
327 results showed that men's small EVs were richer in HIV-1 RNA than women's (Figure S5).
328 This data suggests again that the HIV-1 RNA in small EVs could be linked to NSV.

329

330 HIV-1 RNA in large EVs was susceptible to treatment, suggesting it is the product of active
331 viral replication. These observations corroborate the previous assessment of viral RNA in large
332 and small EVs in humanized mice (28). In that study, mice treatment lowered HIV-1 RNA in
333 large EVs only. HIV-1 RNA in humanized mice small EVs correlated positively with the CD4

334 and CD4/CD8 ratio. The same correlation was observed in PLWH small EVs with a positive
335 CD4/CD8 ratio. Viral replication causes a loss of CD4 T lymphocytes and expansion of CD8
336 T lymphocytes (6, 30). This strengthens the hypothesis that HIV-1 RNA in small EVs is not the
337 product of viral replication. The hypothesis that large EVs contain HIV-1 RNA from active
338 viral replication and small EVs contain HIV-1 RNA from provirus transcription could be
339 explored by RNA sequencing. Viral replication will result in more genetic diversity due to the
340 error-prone reverse transcriptase (31). On the contrary, HIV-1 RNA from NSV is less diverse
341 since it comes from the transcriptional activity of clonally expanded CD4 T lymphocytes (7,
342 32). The Nanopore sequencing technology efficiently detects genetic divergence caused by
343 viral replication (33) and mutations associated with ART resistance (34). Nanopore additionally
344 offers the possibility to sequence the full length HIV-1 genome (35). This novel technology
345 could further characterize the viral RNA associated with EVs subtypes.

346
347 This is the first report of comparative HIV-1 RNA quantification in EV subtypes of PLWH.
348 Viral proteins and genetic material have been generally linked to small EVs (exosomes) because
349 their biogenesis intertwines (36). Viruses can be formed in multivesicular bodies with exosomes
350 (37). HIV-1 assembly also occurs at the plasma membrane (38). Both secretion mechanisms
351 are involved in viral replication in infected cells but their relative contribution to HIV-1
352 pathogenesis has never been explored. Different biogenesis machinery incorporates disparate
353 RNA and microRNA content in large and small EVs (39). This could explain the differential
354 distribution of HIV-1 RNA in large and small EVs among PLWH. In addition, viruses would
355 be associated with different host components whether they form at the plasma membrane or in
356 multivesicular bodies. For example, miR-155 is enriched in large EVs during HIV-1 infection,
357 promoting viral replication in the recipient cell (18). Therefore, viruses related to large EVs
358 could be more infectious due to miR-155 transfer.

359

360 In this study, we showed a differential distribution of HIV-1 RNA in plasmatic EVs subtypes
361 of PLWH. Viral replication was linked to HIV-1 RNA in large EV. Besides, HIV-1 RNA in
362 small EVs was associated with immune restoration. This novel parameter could help us predict
363 HIV-1 infection progression in PLWH and decipher the cause of a viral rebound. Combined
364 with a miRNA analysis, we could establish a nucleic acid profile in EVs associated with
365 immune dysfunction and virological failure to improve PLWH monitoring.

366 **Author contributions:** Conceived and designed the experiments J.B., W.W.B., B.G. and C.G.:
367 Performed the experiments: J.B., W.W.B. and B.G. Analyzed the data: J.B., W.W.B., B.G. and
368 C.G.; Contributed clinical samples, reagents, materials, and analytical tools: J.B., W.W.B. M.A.
369 and C.G.; Wrote the manuscript: J.B. and C.G. All authors have critically reviewed the paper
370 and have agreed on the published version of the manuscript.

371

372 **Competing interests:**

373 The authors declare that the research was conducted without any commercial or financial
374 relationships construed as a potential conflict of interest.

375

376 **Acknowledgements:** This research was funded through Canadian Institutes of Health Research
377 (CIHR) grants MOP-391232; MOP-188726; MOP-267056 (HIV/AIDS initiative) to C.G. J.B.
378 and W.B.B. are the recipient of the Desjardins scholarship from the Fondation du CHU de
379 Québec. J.B. and W.B.B. are recipients of the recruitment scholarship from the AIDS Research
380 Fund of Université Laval. W.W.B. is the recipient of the leadership and sustainable
381 development scholarship and the Fonds de Recherche du Québec – Santé (FRQ-S) doctoral
382 training scholarship. The FRQ-S supports the Centre de recherche du CHU de Québec –
383 Université Laval infrastructure. The authors thank Drs. Martin Pelletier and Stephane Gobeil
384 for access to the qPCR platform. We are very grateful to the study participants, without whom
385 this study would not have been feasible.

386

387 **Institutional review board statement:** The study was conducted according to the guidelines
388 of the Declaration of Helsinki and approved by the Centre de Recherche du CHU de Québec-
389 Université Laval (Québec, QC, Canada) ethics review boards C12-03-208 (2012-2021) and

390 CER-2019-4258. All subjects were volunteers and provided written informed consent before
391 participating in the study.

392

393 **Informed consent statement:** Written informed consent was obtained from all subjects
394 involved in the study.

395

396 **Data availability statement:**

397 The study protocol, results and informed consent documents will be made available to
398 researchers upon request from the corresponding author. Researchers will be asked to complete
399 a concept sheet for their proposed analyses to be reviewed, and the investigators will consider
400 the overlap of the proposed project with active or planned analyses and the appropriateness of
401 the study data for the proposed analysis.

402

403 Bibliography

- 404 1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a
405 T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
406 *Science*. 1983;220(4599):868-71.
- 407 2. Gupta PK, Saxena A. HIV/AIDS: Current Updates on the Disease, Treatment and Prevention.
408 *Proc Natl Acad Sci India Sect B Biol Sci*. 2021;91(3):495-510.
- 409 3. Sankaranantham M. HIV - Is a cure possible? *Indian J Sex Transm Dis AIDS*. 2019;40(1):1-5.
- 410 4. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, Collier AC, et al. Rebound of
411 plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV
412 reservoir: implications for eradication. *Aids*. 2010;24(18):2803-8.
- 413 5. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, et al. Antiretroviral drug
414 resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line
415 therapy. *The Journal of infectious diseases*. 2011;204(4):515-20.
- 416 6. Gupta-Wright A, Fielding K, van Oosterhout JJ, Alufandika M, Grint DJ, Chimbayo E, et al.
417 Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi:
418 an observational cohort study. *The Lancet HIV*. 2020;7(9):e620-e8.
- 419 7. White JA, Wu F, Yasin S, Moskovljevic M, Varriale J, Dragoni F, et al. Clonally expanded HIV-1
420 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia. *J Clin Invest*.
421 2023;133(6).
- 422 8. Wu F, Simonetti FR. Learning from Persistent Viremia: Mechanisms and Implications for
423 Clinical Care and HIV-1 Cure. *Curr HIV/AIDS Rep*. 2023;20(6):428-39.
- 424 9. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment
425 intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral
426 therapy. *Proc Natl Acad Sci U S A*. 2009;106(23):9403-8.
- 427 10. Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, et al. Viral and host mediators
428 of non-suppressible HIV-1 viremia. *Nat Med*. 2023;29(12):3212-23.
- 429 11. Bazié WW, Boucher J, Vitry J, Goyer B, Routy JP, Tremblay C, et al. Plasma Extracellular
430 Vesicle Subtypes May be Useful as Potential Biomarkers of Immune Activation in People With HIV.
431 *Pathog Immun*. 2021;6(1):1-28.
- 432 12. Bazié WW, Boucher J, Traoré IT, Kania D, Somé DY, Alary M, et al. Vesicular MicroRNA as
433 Potential Biomarkers of Viral Rebound. *Cells*. 2022;11(5).
- 434 13. Hubert A, Subra C, Jenabian MA, Tremblay Labrecque PF, Tremblay C, Laffont B, et al.
435 Elevated Abundance, Size, and MicroRNA Content of Plasma Extracellular Vesicles in Viremic HIV-1+
436 Patients: Correlations With Known Markers of Disease Progression. *Journal of acquired immune*
437 *deficiency syndromes (1999)*. 2015;70(3):219-27.
- 438 14. Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal
439 information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. *J*
440 *Extracell Vesicles*. 2024;13(2):e12404.
- 441 15. Tricarico C, Clancy J, D'Souza-Schorey C. Biology and biogenesis of shed microvesicles. *Small*
442 *GTPases*. 2017;8(4):220-32.
- 443 16. Han Q-F, Li W-J, Hu K-S, Gao J, Zhai W-L, Yang J-H, et al. Exosome biogenesis: machinery,
444 regulation, and therapeutic implications in cancer. *Molecular Cancer*. 2022;21(1):207.
- 445 17. Dixon AC, Dawson TR, Di Vizio D, Weaver AM. Context-specific regulation of extracellular
446 vesicle biogenesis and cargo selection. *Nature Reviews Molecular Cell Biology*. 2023;24(7):454-76.
- 447 18. Boucher J, Rousseau A, Boucher C, Subra C, Bazié WW, Hubert A, et al. Immune Cells Release
448 MicroRNA-155 Enriched Extracellular Vesicles That Promote HIV-1 Infection. *Cells*. 2023;12(3).
- 449 19. Bazié WW, Boucher J, Goyer B, Traoré IT, Kania D, Somé DY, et al. Plasma vesicular miR-155
450 as a biomarker of immune activation in antiretroviral treated people living with HIV. *Front Immunol*.
451 2022;13:916599.

- 452 20. Narayanan A, Iordanskiy S, Das R, Van Duyne R, Santos S, Jaworski E, et al. Exosomes derived
453 from HIV-1-infected cells contain trans-activation response element RNA. *J Biol Chem.*
454 2013;288(27):20014-33.
- 455 21. Columba Cabezas S, Federico M. Sequences within RNA coding for HIV-1 Gag p17 are
456 efficiently targeted to exosomes. *Cellular Microbiology.* 2013;15(3):412-29.
- 457 22. Barclay RA, Schwab A, DeMarino C, Akpamagbo Y, Lepene B, Kassaye S, et al. Exosomes from
458 uninfected cells activate transcription of latent HIV-1. *J Biol Chem.* 2017;292(28):11682-701.
- 459 23. Hladnik A, Ferdin J, Goričar K, Deeks GS, Peterlin MB, Plemenitaš A, et al. Trans-Activation
460 Response Element RNA is Detectable in the Plasma of a Subset of Aviremic HIV-1-Infected Patients.
461 *Acta Chim Slov.* 2017;64(3):530-6.
- 462 24. Bazié WW, Boucher J, Goyer B, Kania D, Traoré IT, Somé DY, et al. HIV Replication Increases
463 the Mitochondrial DNA Content of Plasma Extracellular Vesicles. *Int J Mol Sci.* 2023;24(3).
- 464 25. Bazié WW, Goyer B, Boucher J, Zhang Y, Planas D, Chatterjee D, et al. Diurnal Variation of
465 Plasma Extracellular Vesicle Is Disrupted in People Living with HIV. *Pathogens.* 2021;10(5).
- 466 26. Rio DC, Ares M, Jr., Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). *Cold*
467 *Spring Harb Protoc.* 2010;2010(6):pdb.prot5439.
- 468 27. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, et al. Transfer and evaluation
469 of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of
470 human immunodeficiency virus type 1 infection in a West African resource-limited setting. *J Clin*
471 *Microbiol.* 2005;43(6):2709-17.
- 472 28. Boucher J, Pépin G, Goyer B, Hubert A, Bazié WW, Vitry J, et al. Exploring the Relationship
473 Between Extracellular Vesicles, the Dendritic Cell Immunoreceptor and MicroRNA-155 in an In Vivo
474 Model of HIV-1 Infection to Understand the Disease and Develop New Treatments. *bioRxiv.*
475 2024:2024.10.18.619157.
- 476 29. Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, et al. Association of Male Sex
477 and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-
478 Term Antiretroviral Therapy. *The Journal of infectious diseases.* 2021;223(3):462-70.
- 479 30. Eller Michael A, Goonetilleke N, Tassaneetrithep B, Eller Leigh A, Costanzo Margaret C,
480 Johnson S, et al. Expansion of Inefficient HIV-Specific CD8 T Cells during Acute Infection. *Journal of*
481 *virology.* 2016;90(8):4005-16.
- 482 31. O'Neil PK, Sun G, Yu H, Ron Y, Dougherty JP, Preston BD. Mutational analysis of HIV-1 long
483 terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II
484 to viral mutagenesis. *J Biol Chem.* 2002;277(41):38053-61.
- 485 32. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, et al. HIV latency. Specific HIV
486 integration sites are linked to clonal expansion and persistence of infected cells. *Science.*
487 2014;345(6193):179-83.
- 488 33. Ode H, Matsuda M, Shigemi U, Mori M, Yamamura Y, Nakata Y, et al. Population-based
489 nanopore sequencing of the HIV-1 pangenome to identify drug resistance mutations. *Scientific*
490 *reports.* 2024;14(1):12099.
- 491 34. Park SY, Faraci G, Ganesh K, Dubé MP, Lee HY. Portable Nanopore sequencing solution for
492 next-generation HIV drug resistance testing. *J Clin Virol.* 2024;171:105639.
- 493 35. Wright IA, Delaney KE, Katusiime MGK, Botha JC, Engelbrecht S, Kearney MF, et al. NanoHIV:
494 A Bioinformatics Pipeline for Producing Accurate, Near Full-Length HIV Proviral Genomes Sequenced
495 Using the Oxford Nanopore Technology. *Cells.* 2021;10(10).
- 496 36. Meng B, Ip NCY, Abbink TEM, Kenyon JC, Lever AML. ESCRT-II functions by linking to ESCRT-I
497 in human immunodeficiency virus-1 budding. *Cellular Microbiology.* 2020;22(5):e13161.
- 498 37. Pelchen-Matthews A, Kramer B, Marsh M. Infectious HIV-1 assembles in late endosomes in
499 primary macrophages. *J Cell Biol.* 2003;162(3):443-55.
- 500 38. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release.
501 *Proc Natl Acad Sci U S A.* 2001;98(24):13925-30.

502 39. Crescitelli R, Lässer C, Szabó TG, Kittel A, Eldh M, Dianzani I, et al. Distinct RNA profiles in
503 subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. *J Extracell*
504 *Vesicles*. 2013;2.
505